prostate cancer
Conditions
Interventions
experimental group:Docetaxel chemoembolization
control group:Docetaxel systemic chemotherapy
Sponsors
Hospital of Chengdu University of Traditional Chinese Medicine
Eligibility
Sex/Gender
Male
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Prostate cancer confirmed by tissue or cytology; 2) Compliance with diagnostic criteria for castration-resistant prostate cancer; 3) Life expectancy greater than 12 weeks; 4) Aged 18-75 years; 5) Voluntary signing of informed consent.
Exclusion criteria
Exclusion criteria: 1) Severe cardiopulmonary insufficiency; 2) Severe damage of bone marrow hematopoietic function; 3) Contrast agent allergy or known severe allergy to research drugs; 4) Multiple bone metastases; 5) Previously received embolization or chemotherapy; 6) Intolerance to interventional surgery or have other serious diseases; 7) The researchers judged any instability or may endanger the safety of subjects and the compliance of their studies; Complications or social environment that can cause subjects not to follow the research plan or even endanger the safety of patients; 8) Subjects who were not considered suitable for this regimen.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;objective remission rate;disease control rate;the influence of quality of life;hospital days;Economic cost of hospitalization; | — |
Countries
China
Contacts
Public ContactYuan Liu
Hospital of Chengdu University of Traditional Chinese Medicine
Outcome results
None listed